Table of Contents
WILMINGTON, Mass. — CutisPharma plans to award an unrestricted grant to the C Diff Foundation to further support its efforts to raise awareness of Clostridium difficile infection (C. difficile).
A serious gastrointestinal infection, C. difficile — also known as C diff. — typically affects people who are on antibiotic therapy and/or have experienced a long-term hospitalization or an extended stay in a long-term care facility. Though older adults are more at risk, a rising number of younger adults also have developed C. diff infection, which can be spread by simply not washing hands after being exposed to the bacteria.
CutisPharma announced the grant on Wednesday, the first day of Clostridium Difficile Awareness Month.
“We are pleased to partner with the C Diff Foundation and support its education and advocacy efforts benefiting patients impacted by Clostridium difficile infection,” stated Neal Muni, chief executive officer of CutisPharma. “It’s our hope that our work together can make positive strides in building awareness of this life-threatening condition that affects over a half-million patients in the United States annually.”
The nonprofit C Diff Foundation focuses on supporting global public health initiatives for C. difficile for infection prevention, treatments and environmental safety.
“I am very thankful for CutisPharma’s support of our foundation’s efforts,” commented Nancy Caralla, founder and executive director of the C Diff Foundation, who is a nurse and a three-time C. difficile survivor and lost her father to a C. difficile infection. “CutisPharma’s mission to improve the lives of patients with unmet medical needs is aligned with our foundation’s goals, and we look forward to partnering with Neal and his team to further our education and advocacy efforts on behalf of patients and survivors.”
CutisPharma noted that it recently has undertaken initiatives to expand from its traditional business of making compounding kits for pharmacists to include the development and commercialization of Food and Drug Administration-approved drugs. Earlier this year, CutisPharma’s RM Therapeutics subsidiary filed the company’s first FDA New Drug Application (NDA).
